Study Title: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Theodore Gourdin, at gourdith@musc.edu.Study Coordinator, Renee Tucker, at tuckerr@musc.edu.Trial opened at the following institutions: Medical University of South Carolina